1. Home
  2. Analysis
  3. Vyvanse
  4. Injection-site-erythema

Vyvanse and Injection site erythema - a phase IV clinical study of FDA data

Summary:

Injection site erythema is reported as a side effect among people who take Vyvanse (lisdexamfetamine dimesylate), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Humira, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Injection site erythema when taking Vyvanse. It is created by eHealthMe based on reports of 28,083 people who have side effects when taking Vyvanse from the FDA, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,870 Vyvanse users. Check the latest studies of Vyvanse.

What is Injection site erythema?

Injection site erythema (redness at injection site) is found to be associated with 1,450 drugs and 1,417 conditions by eHealthMe. Check the latest studies of Injection site erythema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

28,083 people reported to have side effects when taking Vyvanse.
Among them, 62 people (0.22%) have Injection site erythema.

Could Vyvanse cause Injection site erythema?

Among these 62 people:

How long have people been on Vyvanse when they have Injection site erythema? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Injection site erythema when taking Vyvanse? *

  • female: 71.67 %
  • male: 28.33 %

What is the age of people who have Injection site erythema when taking Vyvanse? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 19.05 %
  • 20-29: 16.67 %
  • 30-39: 35.71 %
  • 40-49: 16.67 %
  • 50-59: 9.52 %
  • 60+: 2.38 %

What are other drugs people take besides Vyvanse? *

  1. Humira: 10 people, 16.13%
  2. Vivitrol: 6 people, 9.68%
  3. Enbrel: 6 people, 9.68%
  4. Vitamin D2: 5 people, 8.06%
  5. Prednisone: 5 people, 8.06%
  6. Acetaminophen: 5 people, 8.06%
  7. Tramadol: 5 people, 8.06%
  8. Gabapentin: 5 people, 8.06%
  9. Dupixent: 5 people, 8.06%
  10. Methotrexate: 4 people, 6.45%

What are other side effects people have besides Injection site erythema? *

  1. Injection Site Pain: 29 people, 46.77%
  2. Injection Site Pruritus (severe itching at injection site): 23 people, 37.10%
  3. Injection Site Swelling: 22 people, 35.48%
  4. Injection Site Mass: 13 people, 20.97%
  5. Injection Site Reaction: 12 people, 19.35%
  6. Injection Site Warmth: 11 people, 17.74%
  7. Injection Site Bruising: 11 people, 17.74%
  8. Fatigue (feeling of tiredness): 8 people, 12.90%
  9. Injection Site Urticaria (rash of round, red welts on the skin at injection site): 8 people, 12.90%
  10. Headache (pain in head): 8 people, 12.90%

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 8 people, 12.90%
  2. Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 5 people, 8.06%
  3. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 8.06%
  4. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 6.45%
  5. Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 6.45%
  6. Drug Dependence: 4 people, 6.45%
  7. Psoriasis (immune-mediated disease that affects the skin): 4 people, 6.45%
  8. Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 4.84%
  9. Thyroid Diseases: 3 people, 4.84%
  10. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 4.84%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and have Injection site erythema?

- Check whether Injection site erythema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyvanse:

Injection site erythema treatments and more:

How severe was Injection site erythema and when was it recovered:

Expand to all the drugs that have ingredients of lisdexamfetamine dimesylate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vyvanse:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site erythema:

Browse all the conditions that are associated with Injection site erythema:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on lisdexamfetamine dimesylate (the active ingredients of Vyvanse) and Vyvanse (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.